Skip to main navigation INVESTORS Investor Resources FAQs Online Investor Kit Email Alerts Contact IR Where is Forma’s corporate headquarters located? When did Forma go public? What is Forma’s CUSIP number? Does Forma have a direct stock purchase plan? Does Forma pay dividends and have a dividend reinvestment program? When is Forma’s fiscal year-end? How is Forma stock traded? Who is Forma’s transfer agent? Who are Forma’s independent auditors? Who is Forma’s legal counsel? How can I view documents Forma has filed with the Securities & Exchange Commission (SEC)? Where can I get the latest corporate news releases and financial reports? Whom should I contact if I have further questions? How can I find out about the next annual meeting? 300 North Beacon Street, Suite 501 Watertown, MA 02472 617.679.1970 Social Links Legal Nav Privacy Policy Terms of Use © 2021 ALL RIGHTS RESERVED

OUR PROGRAMS Glioma OLUTASIDENIB Explore Gliomas are one of the most common types of primary brain tumors. They are aggressive and difficult to treat.1 As with most primary brain tumors, the exact cause of gliomas is unknown.2 More than 70% of individuals with gliomas present with an IDH1 mutation, but treatment options for this group are limited.3 IDH1 mutations also occur in approximately 40% of chondrosarcomas and approximately 20% of intrahepatic cholangiocarcinomas.4 There remains significant unmet medical need for this patient population. 300 North Beacon Street, Suite 501 Watertown, MA 02472 617.679.1970 twitter linkedin instagram facebook glassdoor Privacy Policy Terms of Use © 2021 ALL RIGHTS RESERVED